Immunis, Inc., a clinical-stage biotech developing novel secretome therapeutics for age and disease-related immune dysfunction, is excited to announce that Chairman Dr. Hans Keirstead was a featured speaker at the 2024 LABEST conference. LABEST is held annually at the UCLA Meyer and Renee Luskin Conference Center and affords industry leaders and scientists the opportunity to discuss the evolving ecosystem of the biomedical industry.

From a business standpoint, Dr. Keirstead is an exemplary figure of entrepreneurial success in biotech. His leadership has been instrumental in the development of multiple biotechnology firms, each acquired by major pharmaceutical companies, and providing substantial returns to investors. From a biomedical standpoint, Dr. Keirstead is an accomplished Neuroscientist and former tenured Professor from UC Irvine with numerous patents, and he continues to develop cutting-edge therapies. Both perspectives were instrumental at LABEST in discussing how the biotech community should prioritize therapeutic developments.

Dr. Keirstead shared that “the immune system is the key to our health and immune dysfunction is at the root of all age-related diseases. Thus, a greater effort should be catered towards understanding the diversity of the immune system before we begin to treat it.”

In alignment with this vision, Dr. Keirstead is CEO of the not-for-profit Human Immune Project, which is mapping the immune system in humans of all ages, races, and genders to understand how it evolves in different populations. Additionally, as Chairman of Immunis, Dr. Keirstead is uncovering the potential of human cell-derived secretomes, which contain hundreds of factors that can simultaneously influence numerous biological pathways. Immunis is currently studying how the secretome can reverse the effects of age-related immune dysfunction, including muscle loss and metabolic decline.

Dr. Keirstead is optimistic about the extension of human healthspan as the industry continues to appreciate the nuances of the immune system and design biomedical innovations accordingly.

About Immunis Inc.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com